Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer

Singla,Smit; Pippin,James  A.; Drebin,Jeffrey  A.

doi:10.3892/or.2012.2053

Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer

Authors:
- Smit Singla
- James A. Pippin
- Jeffrey A. Drebin
View Affiliations

Affiliations: Department of Surgery, Temple University Hospital, Philadelphia, PA 19104, USA, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Published online on: September 24, 2012 https://doi.org/10.3892/or.2012.2053
Pages: 2211-2216

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patient survival in pancreatic cancer remains poor with gemcitabine (GEM)-based regimens. The target specific molecular agent lapatinib, a dual ErbB1 and ErbB2 receptor tyrosine kinase inhibitor, has shown significant activity against ErbB1 and ErbB2-expressing tumors. Since pancreatic tumors frequently overexpress these proteins, we investigated its effects, both alone and in conjunction with 5-FU or GEM. The pancreatic cancer cell lines PANC-1 and AsPC were treated with varying doses of lapatinib in vitro. The effects on ErbB1/ErbB2 protein phosphorylation and on the cell survival protein survivin were determined by western blotting. Cytotoxicity was determined by MTT assay and apoptosis was measured using the caspase-3 colorimetric assay. Similar dose-response lapatinib experiments were conducted with varying concentrations of 5-FU or GEM and isobolograms were constructed to evaluate therapeutic synergy. Lapatinib inhibited protein phosphorylation in the range of 4-16 µM, a clinically achievable concentration. The lapatinib-treated cells showed a dose-dependent inhibition of cell proliferation and induction of apoptosis at the same concentrations that blocked ErbB1/ErbB2 phosphorylation. The addition of 5-FU or GEM to these cells resulted in synergistic effects. The lapatinib-treated cells also demonstrated downregulation of survivin. Simultaneous dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition with lapatinib results in significant reduction of pancreatic cancer cell growth and proliferation. These effects occur at clinically achievable concentrations and are synergistic with the effects of 5-FU or GEM. These findings support the potential role of lapatinib in the treatment of pancreatic cancer.

View Figures

View References

1	Nelson NJ: Pancreatic cancer research matures. J Natl Cancer Inst. 99:1432–1434. 2007. View Article : Google Scholar : PubMed/NCBI
2	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar
3	Li J and Saif MW: Any progress in the management of advanced pancreatic cancer? JOP. 10:361–365. 2009.
4	Zhu CP, Shi J, Chen YX, Xie WF and Lin Y: Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol. 99:108–113. 2011. View Article : Google Scholar : PubMed/NCBI
5	Heinemann V, Boeck S, Hinke A, Labianca R and Louvet C: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 8:822008. View Article : Google Scholar
6	Yip D, Karapetis C, Strickland A, Steer CB and Goldstein D: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 3:CD0020932006.
7	Rivera F, Lopez-Tarruella S, Vega-Villegas ME and Salcedo M: Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev. 35:335–339. 2009. View Article : Google Scholar : PubMed/NCBI
8	Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 28:3605–3610. 2010. View Article : Google Scholar
9	Fountzilas G, Bobos M, Kalogera-Fountzila A, et al: Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest. 26:784–793. 2008. View Article : Google Scholar
10	Moore MJ, Goldstein D, Hamm J, et al: National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar
11	Safran H, Iannitti D, Ramanathan R, et al: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress ERBB2/neu. Cancer Invest. 22:706–712. 2004. View Article : Google Scholar : PubMed/NCBI
12	Mendelsohn J and Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene. 19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
13	Riese DJ II and Stern DF: Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 20:41–48. 1998. View Article : Google Scholar : PubMed/NCBI
14	Ueda S, Ogata S, Tsuda H, et al: The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas. 29:e1–e8. 2004. View Article : Google Scholar
15	Dancer J, Takei H, Ro JY and Lowery-Nordberg M: Coexpression of ERBB1 and ERBB2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization. Oncol Rep. 18:151–155. 2007.
16	Tobita K, Kijima H, Dowaki S, et al: Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med. 11:305–309. 2003.PubMed/NCBI
17	Scaltriti M, Rojo F, Ocana A, et al: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 99:628–638. 2007. View Article : Google Scholar : PubMed/NCBI
18	Konecny GE, Pegram MD, Venkatesan N, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66:1630–1639. 2006. View Article : Google Scholar : PubMed/NCBI
19	O’Brien NA, Browne BC, Chow L, et al: Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther. 9:1489–1502. 2010.PubMed/NCBI
20	Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
21	Mehta SP: Palliative chemotherapy for pancreatic malignancies. Surg Clin North Am. 90:365–375. 2010. View Article : Google Scholar : PubMed/NCBI
22	Muthuswamy SK, Gilman M and Brugge JS: Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol. 19:6845–6857. 1999.PubMed/NCBI
23	Zwick E, Hackel PO, Prenzel N and Ullrich A: The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci. 20:408–412. 1999. View Article : Google Scholar : PubMed/NCBI
24	Sorkin A, Helin K, Waters CM, Carpenter G and Beguinot L: Multiple autophosphorylation sites of the epidermal growth factor receptor are essential for receptor kinase activity and internalization. Contrasting significance of tyrosine 992 in the native and truncated receptors. J Biol Chem. 267:8672–8678. 1992.
25	Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998. View Article : Google Scholar : PubMed/NCBI
26	Liu BB and Wang WH: Survivin and pancreatic cancer. World J Clin Oncol. 2:164–168. 2011. View Article : Google Scholar : PubMed/NCBI
27	Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG, Taka S and Gazouli M: Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas. 39:976–980. 2010. View Article : Google Scholar : PubMed/NCBI
28	Shen YM, Yang XC, Song ML, Qin CH, Yang C and Sun YH: Growth inhibition induced by short hairpin RNA to silence survivin gene in human pancreatic cancer cells. Hepatobiliary Pancreat Dis Int. 9:69–77. 2010.PubMed/NCBI
29	Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar : PubMed/NCBI
30	Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J and Jovin TM: Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 65:473–482. 2005.PubMed/NCBI
31	Xia W, Liu LH, Ho P and Spector NL: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene. 23:646–653. 2004. View Article : Google Scholar : PubMed/NCBI
32	Xia W, Mullin RJ, Keith BR, et al: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 21:6255–6263. 2002. View Article : Google Scholar : PubMed/NCBI
33	Song Z, Yao X and Wu M: Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 278:23130–23140. 2003. View Article : Google Scholar : PubMed/NCBI
34	Wang Z, Fukuda S and Pelus LM: Survivin regulates the p53 tumor suppressor gene family. Oncogene. 23:8146–8153. 2004. View Article : Google Scholar : PubMed/NCBI
35	Desplanques G, Hulin P, Juin P and Barille-Nion S: Survivin Protects Breast Cancer Cells from DNA Damage during Mitosis (abstract). In: Thirty-Second Annual CTRC-AACR San Antonio Breast Cancer Symposium; Dec 10–13; San Antonio, TX. pp. 2009Cancer Res. 69(Suppl 3)2009, View Article : Google Scholar
36	Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V and Spector N: Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol. 28:3248–3255. 2010. View Article : Google Scholar : PubMed/NCBI
37	LoRusso PM, Jones SF, Koch KM, et al: Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol. 26:3051–3056. 2008. View Article : Google Scholar : PubMed/NCBI
38	Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 112:533–543. 2008. View Article : Google Scholar
39	Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 27:5538–5546. 2009. View Article : Google Scholar
40	Siegel-Lakhai WS, Beijnen JH, Vervenne WL, et al: Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin Cancer Res. 13:4495–4502. 2007. View Article : Google Scholar
41	Midgley RS, Kerr DJ, Flaherty KT, et al: A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Ann Oncol. 18:2025–2029. 2007. View Article : Google Scholar : PubMed/NCBI